The National Cancer Institute has awarded MRIGlobal a five-year, $3.8 million contract to analyze potential drugs in the fight against cancer.
Kansas City-based MRIGlobal announced the award Friday, saying this is the 12th consecutive contract from the NCI for the Anti-Cancer Chemicals and Pharmaceutical Formulations Analysis Program. The program deals with bulk pharmaceutical substances and drugs, typically before they’re approved by the U.S. Food and Drug Administration.